Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Jahr

2021

Autoren

Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, Havrdová EK, Nakamura K, Traboulsee A, Ziemssen T, Jacobs A, Margolin DH, Huang X, Daizadeh N, Chirieac MC, Selmaj KW.

Verlag

Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134.

Link

https://doi.org/10.1177/1756286420982134

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis